Immunovant Inc’s recent filing unveils that its Chief Medical Officer Geffner Michael unloaded Company’s shares for reported $19998.0 on Jul 09 ’25. In the deal valued at $17.24 per share,1,160 shares were sold. As a result of this transaction, Geffner Michael now holds 224,210 shares worth roughly $4.06 million.
Then, Stout Jay S sold 1,519 shares, generating $26,188 in total proceeds. Upon selling the shares at $17.24, the Chief Technology Officer now owns 207,724 shares.
Before that, WILLIAM MACIAS bought 30,000 shares. Immunovant Inc shares valued at $474,861 were divested by the Officer at a price of $15.83 per share.
A number of analysts have revised their coverage, including Jefferies’s analysts, who began to cover the stock in early March with a ‘”a Hold”‘ rating. Wolfe Research also remained covering IMVT and has decreased its forecast on January 03, 2025 with a “Peer perform” recommendation from previously “an Outperform” rating.
Price Performance Review of IMVT
On Friday, Immunovant Inc [NASDAQ:IMVT] saw its stock jump 3.60% to $18.13. Over the last five days, the stock has gained 6.96%. Immunovant Inc shares have fallen nearly -38.96% since the year began. Nevertheless, the stocks have fallen -26.81% over the past one year. While a 52-week high of $34.47 was reached on 01/02/25, a 52-week low of $12.72 was recorded on 04/09/25.
Levels Of Support And Resistance For IMVT Stock
The 24-hour chart illustrates a support level at 17.39, which if violated will result in even more drops to 16.65. On the upside, there is a resistance level at 18.55. A further resistance level may holdings at 18.97.
How much short interest is there in Immunovant Inc?
A steep rise in short interest was recorded in Immunovant Inc stocks on 2025-06-13, dropping by -1.48 million shares to a total of 19.92 million shares. Yahoo Finance data shows the prior-month short interest on 2025-05-15 was 21.4 million shares. There was a decline of -7.43%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on October 09, 2024 when Oppenheimer resumed its ‘”an Outperform”‘ rating for the stock and retained the price target to $53.
